Investigating how certain genetic mutations affect brain cells in Alzheimer's disease
Role of TREM2 gain-of-function mutations in modulating microglial pathology in Alzheimer's disease
This study is looking at how certain changes in a gene called TREM2 affect brain cells that help keep our brains healthy, especially in the context of Alzheimer's disease, to find new ways to treat or prevent the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11088806 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of specific genetic mutations in the TREM2 gene and how they influence the behavior of microglial cells, which are crucial for brain health. By studying these mutations in mouse models of Alzheimer's disease, the researchers aim to uncover how they affect the progression of amyloid beta pathology and neurodegeneration. The approach includes genetic profiling and analysis of microglial responses to amyloid plaques, which could provide insights into potential therapeutic targets for Alzheimer's disease. Patients may benefit from findings that could lead to new treatments or preventive strategies for Alzheimer's.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of Alzheimer's disease or those who carry specific TREM2 gene mutations.
Not a fit: Patients without a genetic predisposition to Alzheimer's disease or those who do not exhibit symptoms of cognitive decline may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve outcomes for patients with Alzheimer's disease.
How similar studies have performed: Previous studies have shown promising results in understanding the role of immune response genes in Alzheimer's disease, indicating that this approach has potential for success.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Griciuc, Ana — Massachusetts General Hospital
- Study coordinator: Griciuc, Ana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.